Last reviewed · How we verify
YL201 and atezolizumab
YL201 and atezolizumab is a Small molecule drug developed by MediLink Therapeutics (Suzhou) Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | YL201 and atezolizumab |
|---|---|
| Sponsor | MediLink Therapeutics (Suzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (PHASE1)
- A Study of YL201 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YL201 and atezolizumab CI brief — competitive landscape report
- YL201 and atezolizumab updates RSS · CI watch RSS
- MediLink Therapeutics (Suzhou) Co., Ltd. portfolio CI
Frequently asked questions about YL201 and atezolizumab
What is YL201 and atezolizumab?
YL201 and atezolizumab is a Small molecule drug developed by MediLink Therapeutics (Suzhou) Co., Ltd..
Who makes YL201 and atezolizumab?
YL201 and atezolizumab is developed by MediLink Therapeutics (Suzhou) Co., Ltd. (see full MediLink Therapeutics (Suzhou) Co., Ltd. pipeline at /company/medilink-therapeutics-suzhou-co-ltd).
What development phase is YL201 and atezolizumab in?
YL201 and atezolizumab is in Phase 1.